$NUTX

Nutex Health Inc.

1
0
0
—
$43K
Saunders Scott J
0%
See all $NUTX insider activity →
Low

These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap

Nutex Health (NUTX) and Elevance Health (ELV) have outperformed the healthcare sector in 2026, with NUTX up 36% and ELV up 11%. NUTX trades at a P/E of 9, while ELV is at 18, both below the sector average of 29.75. NUTX reported strong earnings growth, and ELV reaffirmed its 2026 guidance, highlighting stabilization in its cost structure.

Nutex Health Approved for Dual Listing on Nasdaq Texas

Nutex Health (NASDAQ: NUTX) received approval to dual-list its common stock on Nasdaq Texas, with trading expected to begin September 23, 2026. The company will maintain its listing on the Nasdaq Global Market under the same ticker symbol, NUTX. The dual listing aims to increase visibility among regional investors while keeping its national and international presence.

NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT

Nutex Health (NASDAQ: NUTX) updated stakeholders on a cybersecurity event, noting that stolen data was published online. The company is analyzing the data and has not yet identified material impacts on operations or financial reporting. Several lawsuits have been filed, but the company cannot predict outcomes or estimate financial impacts. Nutex operates 28 hospital facilities across 12 states.

NUTX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning NUTX (Nutex Health Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent NUTX coverage spans earnings, financial news and corporate actions.

In the last 30 days, NUTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($43K). The most active reporter was Saunders Scott J with 1 filing.

What's driving NUTX

AlphAI scores every news story that mentions NUTX with an AI model for sentiment and relevance, and aggregates insider trades from Nutex Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NUTX

Score
$NUTXLow

These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap

Nutex Health (NUTX) and Elevance Health (ELV) have outperformed the healthcare sector in 2026, with NUTX up 36% and ELV up 11%. NUTX trades at a P/E of 9, while ELV is at 18, both below the sector average of 29.75. NUTX reported strong earnings growth, and ELV reaffirmed its 2026 guidance, highlighting stabilization in its cost structure.

NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT

Nutex Health (NASDAQ: NUTX) updated stakeholders on a cybersecurity event, noting that stolen data was published online. The company is analyzing the data and has not yet identified material impacts on operations or financial reporting. Several lawsuits have been filed, but the company cannot predict outcomes or estimate financial impacts. Nutex operates 28 hospital facilities across 12 states.

Zacks.com featured highlights Nutex, RCM, Remitly and Belden

Zacks.com highlighted four companies with strong net profit margins: Nutex Health (NUTX), RCM Technologies (RCMT), Remitly Global (RELY), and Belden (BDC). Each company's 2026 earnings estimates were revised upward, with NUTX up 32.5%, RCMT up 13.3%, RELY up 13.8%, and BDC up 5.7%. All companies recently beat earnings estimates.

Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act

Nutex Health (NASDAQ: NUTX) commented on a Fifth Circuit ruling invalidating federal QPA calculation rules under the No Surprises Act, which the company says artificially deflated payments. The court ruled insurers cannot include non-negotiated 'ghost rates' and must include bonus payments in QPA calculations. Nutex Health expects this to lead to fairer upfront payments for providers. The ruling may impact the company's financials, but the timeline for new regulations is uncertain.

$NUTXMedAI 8/10

Nutex Health (NUTX) Q2 2026 Earnings Call Transcript

Nutex Health (NUTX) reported Q2 2026 results on an earnings call. Total revenue fell to $210.8M from $244.0M. Net income rose to $65.8M, diluted EPS to $9.38, and adjusted EBITDA to $90.0M. Management cited lower contract services costs from a HaloMD amendment and higher patient visits, plus a hospital expansion pipeline.

$NUTXMedAI 8/10

Nutex Health Q2 Profit Soars As IDR Cost Reductions Drive Margin Gains

Nutex Health (NUTX) reported Q2 2026 results, with net income of $65.8M and diluted EPS of $9.38, versus a net loss of $17.7M a year earlier. Revenue fell 13.6% to $210.8M. The company cited IDR-related cost reductions, including a $52.3M contract services expense decline, and expects normalized historical expenses to drop 25% to 30% prospectively. Shares rose 14.88% to $186.19.

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.

Related tickers